Eli Lilly Shifts Dealmaking Strategy, Fueled by GLP-1 Drug Success
Eli Lilly is strategically deploying its substantial financial gains from GLP-1 drugs like Mounjaro and Zepbound to pursue a more aggressive and diversified acquisition...